Up front payment of around $6 million plus development costs. The rest of the money will be paid out in milestone payments if Pfizer stays. So they haven't invested much yet and could leave after initial results are in. If Pfizer stays then this stock will explode, if they leave...pennies.
The most promising data so far has been for the GVHD indication and we will hear back from the FDA regarding clearance for a Phase 2/3 pivotal trial soon. The Pfizer IBD indication is not be all and end all. Please do some research.